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Abstract
Background/Aims: Single-nucleotide polymorphisms (SNPs) near the interleukin 28B gene (IL28B; interferon [IFN]-l-3) are
associated with outcomes of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection treated with peginterferon
(PEG-IFN) alpha-based antiviral therapy. In this study, we investigated the influence of IL28B polymorphisms on
spontaneous clearance of HBV infection in a large Korean cohort.
Methods: Between January 2007 and June 2010, a total of 208 patients with chronic HBV infection and newly diagnosed
HBV-related hepatocellular carcinoma were recruited as the CC group [HBsAg(+) for .6 months, anti-HBc(+), and anti-HBs(-
)]. In addition, 351 organ donors were stratified into the UE group [n = 106; HBsAg(-), anti-HBc(-), and anti-HBs(-)] or the SC
group [n = 245; HBsAg(-), anti-HBc(+), and anti-HBs(+)]. The SNaPshot ddNTP Primer Extension Kit (Applied Biosystems,
Foster City, CA) was used for SNP detection. Direct full sequencing of the IL28B coding region was attempted.
Results: Regardless of group, rs12979860 CC was most frequently identified (85.0% in UE, 85.9% in SC, and 93.5% in CC,
respectively), whereas rs12979860 TT was not identified in any group. Similarly, rs12980275 AA and rs8099917 TT were most
frequently identified ($85%) regardless of group, whereas rs12980275 GG was identified in only one subject in the SC
group. In addition, rs8099917 GG was not identified. The prevalences of CC in rs12979860, AA in rs12980275, and TT in
rs8099917 were significantly higher in the CC group when compared with the UE and SC group (all P,0.05). Among 19
novel SNPs in the IL28B coding region, the proportions of 6 SNPs were significantly different among the UE, SC, and CC
groups (all P,0.05).
Conclusions: The SNP upstream of IL28B that has the strongest genetic association with HCV recovery has an inverse
influence on HBV recovery. Additional studies are needed to understand the mechanisms of this SNP in HBV infection.
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Introduction
Recently, several independent genome-wide association studies
have shown that genetic polymorphisms at or near the interleukin
28B gene (IL28B; also known as interferon [IFN]-l-3), including
rs12979860, rs12980275, and rs8099917, are associated with
higher rates of sustained virologic response (SVR) in patients with
chronic hepatitis C (CHC) treated with peginterferon (PEG-IFN)
alpha and ribavirin [1–4]. Although the mechanism by which
IL28B influences the response to PEG-IFN therapy has remained
elusive, it is likely that the relationship is not specific to hepatitis C
virus (HCV) infection. Indeed, the type of IFN coded for by IL28B,
IFN-l, has been previously shown to be active against several
other viruses including hepatitis B virus (HBV) [5,6]. Recently, a
human study also demonstrated that IL28B polymorphisms were
independently related to serological responses to PEG-IFN in a
large global cohort of patients with hepatitis B e antigen positive
chronic hepatitis B (CHB), similar to the results from chronic
HCV infection [7,8].
In addition to this association between IL28B polymorphisms
and treatment responses to PEG-IFN, the relationship between
IL28B polymorphism and spontaneous clearance of HCV
infection has also been reported in several previous studies
[1,4,9–11]. However, only one study, as a brief report, investigated
the association between IL28B polymorphism and spontaneous
clearance of HBV infection. The study concluded that the single-
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nucleotide polymorphism (SNP) 4 kb upstream of IL28B
(rs12979860), which has a strong genetic association with HCV
recovery, had no association with spontaneous recovery from
HBV infection [13]. Although it is unknown how rs1297860 affects
the activity of IL28B, the authors proposed that it presumably
alters the immune function to HCV, but not HBV [12].
Therefore, the IL28B polymorphism seems to have similar
influences on both the response to antiviral treatment and
spontaneous clearance in HCV infection, whereas it exhibits
different influences in HBV infection between treatment outcomes
using PEG-IFN and spontaneous clearance [7,12]. However, data
on this issue are extremely rare in terms of explaining the different
influences of IL28B polymorphism on treatment outcomes using
PEG-IFN and spontaneous clearance in HBV infection [7,12].
Furthermore, previous studies have only attempted to characterize
the IL28B polymorphism upstream of the IL28B coding region.
Thus, we first investigated the influence of the IL28B polymor-
phism on HBV infection in a large Korean cohort and evaluated
whether there is any novel polymorphism in the IL28B genome,
especially in the coding region.
Materials and Methods
Patients
Between January 2007 and June 2010, a total of 208 patients
with CHB infection and newly diagnosed CHB-related hepato-
cellular carcinoma (HCC) were prospectively recruited at the
Severance Hospital, Yonsei University College of Medicine, Seoul,
Korea and defined as the CC group [HBsAg(+) for .6 months,
anti-HBc(+), and anti-HBs(-)]. During the study period, a total of
351 subjects who were admitted as living liver or kidney donors
were also prospectively recruited and stratified into the UE group
(n = 106) or SC group (n = 245) according to their HBV serological
markers. Subjects were stratified into the UE group when their
HBV serological markers were HBsAg(-), anti-HBc(-), and anti-
HBs(-), whereas subjects who were HBsAg(-), anti-HBc(+), and
anti-HBs(+) were stratified into the SC group. All subjects were
native Korean and provided written informed consent for
participation and for use of their genetic material for this study.
The study protocol conformed to the ethical guidelines of the 1975
Helsinki Declaration and was approved by the Institutional
Review Board of Severance Hospital.
The exclusion criteria were as follows: (1) no available HBV
serological markers, (2) vaccinated subjects who were positive for
anti-HBs alone, but negative for anti-HBc, (3) HCV or human
Table 1. Primer sequence and polymerase chain reaction condition.
Target name Method Primer sequence Tm (6C)
rs12979860 SNaP shot Forward AGACAACCAGGGTGAAGCAA 65
Reverse CTGCTCGCAGCCTCAGTC
Genotyping CGGAGYGCAATTCAACCCTGGTTC
rs12980275 SNaP shot Forward GAGGAGGGAAGGAAGTTCT 60
Reverse AGGTCTGGTCCTAGTGGTG
Genotyping CCCCGGCAAATATTTAGACACGTC
rs8099917 SNaP shot Forward TCCATGTGTTTATTTGTGC 55
Reverse GGAGAATGCAAATGAGAGA
Genotyping TACAGCATGGTTCCAATTTGGGTGA
Promoter-1 Direct sequencing Forward GGTGGCCTGAGTTTCAGTTC 60
Reverse TGCCCAGAGGCCAATATTTC
Promoter-2 Direct sequencing Forward CCTTCGTCACACCTCAATTC 61
Reverse GGAAGGTATGTTCCCAAGAG
Promoter-3 Direct sequencing Forward GAGCAGGTGGAATCCTCTTG 60
Reverse CCCGGTCATGTCTGTGTC
Exon-intron 1 Direct sequencing Forward GTGGGCAGCCTCTGCATTC 58
Reverse AGCAGAAGCGACTCTTCC
Exon-intron 2 Direct sequencing Forward GGCTAACCTGTGCCTTTG 60
Reverse GGAGCTGGGAGAGGATATG
Exon-intron 3 Direct sequencing Forward CTGACGCTGAAGGTTCTG 62
Reverse CAAATACATAAATAGCGACTGGGTGAC
39 UTR-1 Direct sequencing Forward CTTCCGCCAGTCATGCAAC 60
Reverse TCAAGTGATCCTCCCAACTC
39 UTR-2 Direct sequencing Forward CCTGGATGTGATTGCTCAAG 60
Reverse GGTGGAGAATGACACTCTG
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immunodeficiency virus coinfection, (4) presence of other chronic
liver disease, such as autoimmune hepatitis, toxic hepatitis, or
primary biliary cirrhosis, (5) immunosuppressants, chemotherapy,
or systemic corticosteroids within 3 months at enrollment, and (6)
not a native Korean.
Laboratory Tests
All serum specimens were stored at 270uC before testing.
Human immunodeficiency virus antibody was determined by
enzyme-linked immunoassay (ELISA) with Western blot confir-
mation. HCV antibody and HCV RNA were assayed using
commercially available kits. HBV serological markers for HBsAg,
anti-HBc, and anti-HBs were conducted with ELISAs (Dade
Behring, Marburg, Germany).
IL28B Genotyping
Genomic DNA was extracted using a Qiagen DNA Blood Mini
Kit (Qiagen, Mildren, Germany) according to the manufacturer’s
instructions. Three primer sets were used to amplify three SNPs
(rs12979860, rs12980275, and rs8099917) in the IL28B gene
(Table 1). Reactions were screened by gel electrophoresis with
ethidium bromide staining and the polymerase chain reaction
(PCR) product was purified by a PCR purification kit (Qiagen,
Mildren, Germany).
For detection of the three SNPs (rs12979860, rs12980275, and
rs8099917) near the IL28B gene on chromosome 19, which was
identified in previous studies, primer extension reactions were
performed using SNaPshot ddNTP Primer Extension Kit (Applied
Biosystem, Foster City, CA). These SNPs were chosen because
they were previously reported in three independent studies
including mostly white and Asian patients with chronic HCV
infection [2,3,11]. To clean up the primer extension reaction, one
unit of shrimp alkaline phosphatase was added to the reaction
mixture, and the mixture was incubated at 37uC for 1 hour
followed by 15 min at 72uC for enzyme inactivation. The DNA
sample, containing extension products and the Genescan 120 Liz
size standard solution, was added to Hi-Di formamide (Applied
Biosystems, Foster City, CA) according to the manufacturer’s
recommendations. The mixture was incubated at 95uC for 5 min
followed by 5 min on ice. The results were analyzed using the ABI
Prism GeneScan and Genotyper program (Applied Biosystems,
Foster City, CA).
Full Sequencing of the IL28B Coding Region
Sequencing of the IL28B coding region was performed using the
primers listed in Table 1. Nine primer sets were used to amplify
the IL28B coding region. PCR products were identified by
electrophoresis, and PCR products were then purified with a PCR
purification kit and direct sequencing by an ABI 310 automated
sequencer (Applied Biosystems, Foster City, CA).
Statistical Analysis
Data are expressed as the median (range), n (%), or n, as
appropriate. Observed numbers of each genotype were compared
with the expected values in order to test whether the sample was in
Hardy-Weinberg equilibrium using the chi-Square test with one
degree of freedom. Haplotypic association analysis was performed
using PLINK version 1.06 (http://pngu.mgh.harvard.edu/
purcell/plink/). The odds ratio (OR) was calculated to indicate
the associated risk and presented with 95% confidence intervals
(CI). A P-value ,0.05 on a two-tailed test was considered
statistically significant. Statistical analyses were performed with
SPSS version 11.0 (SPSS, Inc., Chicago, IL).
Results
Baseline Non-genetic Data
The mean age of the subjects in the UE (53 men and 53
women), SC (135 men and 110 women), and CC groups (153 men
and 55 women) were 38 (median, 38; range, 18–59), 42 (median,
43; range, 18–69), and 44 (median, 45; range, 18–68) years,
respectively. Subjects in the UE group were significantly younger
than those in the SC (P= 0.004) and CC groups (P,0.001). The
proportion of male subjects in UE group (50.0%) was significantly
lower than that in the SC (55.5%, P,0.001) and CC groups
(73.6%, P,0.001). Genotypic analysis of HBV showed that all
subjects in this study had genotype C. IL28B SNP had no
association to age (P.0.05) and was not prominent in different age
group (P.0.05 by one way ANOVA).
Prevalence of rs12979860, rs12980275, and rs8099917 in
the UE, SC, and CC Groups
Excluding cases with failed genotypic analyses (0,26.0%),
genotypes were successfully called for rs12979860 in 100 of 106
(94.3%) subjects in the UE group, 220 of 245 (89.8%) in the SC
group, and 154 of 208 (74.0%) in the CC group, respectively; for
rs12980275 in 106 of 106 (100%) subjects in the UE group, 243 of
245 (99.2%) in the SC group, and 203 of 208 (97.6%) in the CC
group, respectively; and for rs8099917 in 106 of 106 (100%)
subjects in the UE group, in 241 of 245 (98.4%) in the SC group,
and in 204 of 208 (98.1%) in the CC group, respectively (Table 2).
Regardless of group, rs12979860 CC was most frequently
identified in more than 85% of patients in each group (85.0% in
the UE, 85.9% in the SC, and 93.5% in the CC group,
respectively), whereas rs12979860 TT were not identified in any
group (0% in all groups) (Table 2). Similarly, rs12980275 AA and
rs8099917 TT were most frequently identified ($85%) regardless
of subject group, whereas rs12980275 GG was identified in only
one subject in the SC group and rs8099917 GG was not identified
(Table 2). The prevalence of CC in rs12979860, AA in
rs12980275, and TT in rs8099917 was significantly higher in the
CC group than in the UE and SC groups (all P,0.05) (Table 2).
In addition, allelic frequency of three IL28B SNPs is also described
in Table 2. All genotype frequencies of these SNPs were in Hardy-
Weinberg equilibrium (P= 0.172, 0.382, and 0.227, respectively).
Full Sequencing of the IL28B Coding Region
Fifty samples from each group (150 samples total) were
randomly selected for full sequencing of the IL28B coding region.
The primer sequences that were used for full sequencing are
described in Table 1. Among 19 novel SNPs that were identified
in our study (Figure 1), the proportions of 6 SNPs (SNP 2, 5, 7, 8,
17 and 19) were significantly different among the UE, SC, and CC
groups (all P,0.05).
Prevalence of Newly Identified Novel SNPs in the IL28B
Coding Region
In addition to the 150 samples that were used for full sequencing
of the IL28B gene, 137 samples from the SC group and 109
samples from the CC group that remained after analyzing the
3 SNPs (rs12979860, rs12980275, and rs8099917) were addition-
ally used for investigation of the 6 novel SNPs in the IL28B coding
region.
Although 13.9% to 19.8% of SNaPshot analyses failed in the SC
group and 66.1% to 83.5% in the CC group, SNP2 TT (84.0–
86.3%), SNP5 CC (92.0–97.1%), SNP7 GG (84.0–92.7%), SNP8
GG (84.0–94.7%), SNP17 AA (94.0–98.8%), and SNP19 GG
IL28B Polymorphism in Hepatitis B Virus Infection
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(82.0–93.0%) were most frequently identified regardless of subject
group (Table 3). In contrast, only one case each of SNP2 CC,
SNP7 AA, and SNP8 CC was identified in the CC group, whereas
only one case of SNP17 GG was noted in the SC group (Table 3).
Only the prevalence of SNP8 GG was significantly higher in the
CC group (P= 0.026; odds ratio, 0.219, 95% CI, 0.055–0.870),
where the prevalence of SNP19 GG trended higher in the CC
group (P= 0.051). In addition, allelic frequency of six novel SNPs
is also described in Table 3. All genotype frequencies of these
SNPs were in Hardy-Weinberg equilibrium (P= 0.865, 0.715,
0.871, 0.799, 0.180, and 0.259, respectively).
Haplotypic Combinations
Haplotypic combination using rs12979860, rs12980275, and
rs8099917 did not show statistically better odds ratio (all P.0.05).
However, when we performed haplotypic combination analysis
using rs12979860, rs12980275, rs8099917 and newly identified
19 SNPs, four haplotypic combinations were significantly different
between SC and CC groups (Table 4).
Discussion
IL28B (IFN l3) triggers a cascade through the JAK-STAT
pathway that upregulates the IFN-stimulated genes (ISGs) [13,14].
The effects of IL28B are similar to those of type I IFNs such as
IFN-a and -b; however, IL28B binds to a distinct receptor that
may modulate a different set of ISGs [15]. Recently, this cytokine
was identified as a key factor of the immune response to HCV.
Indeed, there has been increasing evidence showing that an IL28B
haplotype strongly determines both the outcome of natural and
IFN-a-treated HCV infection [1–5].
Because IFN-a and ISGs are thought to be important in the
immune response to HBV, and PEG-IFN-a is used to treat
chronic HBV infection similar to HCV infection, we can assume
that IL28B may also be important in treatment and recovery from
HBV infection. Currently, two reports investigated the clinical role
of the IL28B polymorphism in HBV infection are currently
available [7,12]. One study investigated whether the IL28B
polymorphism is associated with responses to PEG-IFN in patients
with hepatitis B e antigen positive CHB and proposed that
polymorphisms near IL28B are independently associated with
serological responses to PEG-IFN in CHB [7]. The other study
investigated whether the polymorphism marking the haplotype
(rs12979860) also affects other INF-a responsive chronic viral
illness, namely HBV, and concluded that the rs12979860 CC
genotype was not associated with spontaneous HBV recovery [12].
Therefore, in contrast to HCV infection, the IL28B polymorphism
seems to act via different mechanism in terms of treatment
outcomes using INF-a and spontaneous clearance in HBV
infection.
In our study, to determine the potential influence of the IL28B
polymorphism on HBV infection outcome in a natural history
setting, we genotyped this polymorphism in HBV cohorts
comprising subjects who spontaneously cleared HBV or had
persistent infection and those who were never exposed to HBV
infection. In contrast to a previous study [12], our study
Table 2. Prevalence of three SNPs (rs12979860, rs12980275, and rs8099917) in UE, SC, and CC groups.
SNP UE (n=106) SC (n =245) CC (n =208) P value
UE vs. CC/SC vs. CC
rs12979860
Analyzed samples 100 220 154
CC 85 (85.0) 189 (85.9) 144 (93.5) 0.039/0.013
CT 15 (15.0) 31 (14.1) 10 (6.5)
TT 0 (0) 0 (0) 0 (0)
C allele 185 409 298 0.030/0.025
T allele 15 31 10
rs12980275
Analyzed samples 106 243 203
AA 90 (85.0) 208 (85.6) 185 (91.1) 0.018/0.042
AG 16 (15.0) 34 (14.0) 18 (8.9)
GG 0 (0) 1 (0.4) 0 (0)
A allele 196 450 388 0.107/0.064
G allele 16 36 18
rs8099917
Analyzed samples 106 241 204
TT 90 (85.0) 215 (89.2) 192 (94.1) 0.017/0.035
TG 16 (15.0) 26 (10.8) 12 (5.9)
GG 0 (0) 0 (0) 0 (0)
T allele 196 456 396 0.009/0.071
G allele 16 26 12
Variables are expressed as n or n (%).
UE, Subjects who were never exposed to HBV infection; SC, Subjects with spontaneous HBV clearance; CC, subjects with CHB or CHB-related HCC.
SNP, single-nucleotide polymorphism; HBV, hepatitis B virus, CHB, chronic hepatitis B, HCC; hepatocellular carcinoma.
doi:10.1371/journal.pone.0069166.t002
IL28B Polymorphism in Hepatitis B Virus Infection
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e69166
demonstrated that IL28B polymorphisms (rs12979860,
rs12980275, and rs8099917) are significantly associated with the
outcomes of HBV infection (Table 2). However, the prevalence of
the major alleles rs12979860 CC, rs12980275 AA, and rs8099917
TT (.85%), which are favorable predictors in terms of
spontaneous clearance of HCV infection, were unexpectedly
higher in subjects who did not clear HBV than in those who
experienced spontaneous clearance of HBV or those without
exposure to HBV infection. This high prevalence of the major
IL28B polymorphism alleles has been reported in several previous
Korean studies [16] and is consistently higher than the reported
prevalences from Western studies [9]. Based on this finding, higher
SVR rates in Korean patients with CHC have recently been
reported [16]. However, because IFN-based treatment outcomes
have not been investigated in Korean patients with CHB showing
a high prevalence of major IL28B polymorphism alleles, further
studies are needed to investigate whether the IFN-based treatment
outcomes for CHB are similar to those of Western data adjusting
for the influence of HBV genotype (nearly 100% of genotype C in
Korea).
Figure 1. Genomic position of novel SNPs in the IL28B coding region (A) and linkage disequilibrium map (B). Among the 19 novel SNPs
identified, the proportion of 6 SNPs (SNP 2, 5, 7, 8, 17, and 19) were significantly different among the UE, SC, and CC groups (all P,0.05).
doi:10.1371/journal.pone.0069166.g001
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Considering that prior studies have shown that IL28B
polymorphism is associated with spontaneous and treatment-
induced clearance of HCV and has one of the strongest known
genetic associations with any chronic viral infection to date [1–5],
we can assume that IL28B polymorphisms have a distinct effect on
the immune response to HCV in spite of the same signal from both
type I IFNs and IL28B through the JAK-STAT pathway. Because
ISGs were shown to be a major mechanism of non-cytolytic
inhibition of HBV replication in a transgenic mouse model [17]
and IFN-l2 (IL28A) inhibits HBV replication through upregu-
lated ISGs in HCC cell lines [18], it is difficult to explain the
negative correlation between major alleles of IL28B polymorphism
and HBV spontaneous clearance given that IL28B stimulates
ISGs, which play an important role in the immune response to
HBV infection. However, differences between HBV and HCV
infection in terms of their replication strategies, pathways to viral
persistence and clearance, and host responses, including the
production of type I IFNs, are well known [19]. In addition,
Table 3. Prevalence of newly identified six SNPs in IL28B gene in UE, SC, and CC groups.
SNP UE (n=50) SC (n=162) CC (n =80) UE vs. CC SC vs. CC
P value OR 95% CI P value OR 95% CI
SNP2
TT 42 (84.0) 145 (89.5) 69 (86.3) 0.611 – – 0.665 – –
CT 8 (16.0) 17 (10.5) 10 (12.5)
CC 0 (0) 0 (0) 1 (1.2)
T allele 92 307 148 0.883 0.326
C allele 8 17 12
SNP5
CC 46 (92.0) 158 (96.3) 66 (97.1) 0.137 – – 0.999 – –
CT 4 (8.0) 6 (3.7) 2 (2.9)
TT 0 (0) 0 (0) 0 (0)
C allele 96 322 134 0.406 0.787
T allele 4 6 2
SNP7
GG 42 (84.0) 144 (89.4) 64 (92.7) 0.121 – – 0.324 – –
GA 8 (16.0) 17 (10.6) 4 (5.8)
AA 0 (0) 0 (0) 1 (1.5)
G allele 92 305 132 0.238 0.674
A allele 8 17 6
SNP8
GG 42 (84.0) 143 (89.4) 72 (94.7) 0.026 0.219 0.055–0.870 0.131 – –
GC 8 (16.0) 17 (10.6) 3 (3.9)
CC 0 (0) 0 (0) 1 (1.4)
G allele 92 303 147 0.098 0.330
C allele 8 17 5
SNP17
AA 49 (98.0) 158 (94.0) 86 (98.8) 0.999 – – 0.171 – –
AG 1 (2.0) 9 (5.4) 1 (1.2)
GG 0 (0) 1 (0.6) 0 (0)
A allele 99 325 172 0.999 0.067
G allele 1 11 1
SNP19
GG 41 (82.0) 146 (86.9) 80 (93.0) 0.051 – – 0.203 – –
GA 9 (18.0) 22 (13.1) 6 (7.0)
AA 0 (0) 0 (0) 0 (0)
G allele 91 314 16 0.055 0.153
A allele 9 22 6
Variables are expressed as n (%).
UE, Subjects who were never exposed to HBV infection; SC, Subjects with spontaneous HBV clearance;
CC, subjects with CHB or CHB-related HCC.
SNP, single-nucleotide polymorphism; HBV, hepatitis B virus, CHB, chronic hepatitis B, HCC; hepatocellular carcinoma; CI, confidence interval.
doi:10.1371/journal.pone.0069166.t003
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several unique characteristics of IL28B may explain this unex-
pected finding. In addition to inducing ISG expression, IL28B may
activate alternate antiviral pathways, such as the adaptive immune
response, which may be more important in HCV [20]. IL28B may
also lead to a different antiviral state than type I IFNs, in terms of
the upregulation of different ISGs and different speeds of
phosphorylation of STAT1 and STAT2 [15]. It is also possible
that the IL28B pathway may respond differently to HCV and
HBV (more dominant in HCV), which can lead to a different
effect on HCV and HBV infection. Some previous studies support
this hypothesis by proposing lower antiviral activities of IFN- l2
(IL28A) and IFN-l1 (IL29) [16,18], although extrapolation of
these findings to IL28B should be determined. Finally, it is also
plausible that the IL28B and IFN-a pathways are synergistic
because of common downstream signaling pathways and that this
synergism results in different immune responses to HCV and
HBV. However, all of these assumptions, including a lack of
influence of the major IL28B polymorphism alleles on HBV
clearance [10] or the negative influence observed in our study,
should be validated in future work.
Interestingly, we found one novel SNP in the IL28B gene
(SNP8) that was located immediately ahead of the IL28B exon 1
(Figure 1). Its major allele (GG) prevalence was significantly
higher in subjects with persistent HBV infection (Table 3),
although we failed to obtain SNP data in a number of cases using
the SNaPshot assay, possibly because of high homology in the
nucleotide arrangement on chromosome 19. Thus, we could
assume that the genomic site of the SNP8 polymorphism might
serve as a binding area for certain transcriptional factors or
polymerases and may therefore control gene expression levels by
regulating binding capacity. However, functional studies such as
reporter assays are needed to validate this assumption. In addition,
four haplotypic combinations were significantly different between
SC and CC groups. However, further studies are required to
reveal the clinical relevance of these haplotypic combinations.
Our study has several strengths. First, this is the first Korean
study to focus on the influence of the IL28B polymorphism on the
natural clearance of HBV infection and to investigate IL28B
polymorphisms in a healthy Korean population. Thus, our results
can help establish the worldwide database of IL28B polymor-
phisms not only for subjects with persistent HBV infection, but
also for apparently healthy populations. Second, although the
IL28B polymorphism has been known to have a significant
correlation with IFN-based treatment of HCV and spontaneous
clearance of HCV infection, how this polymorphism influences
gene expression levels relatively far from the actual IL28B coding
region has been unclear. Thus, in our study, we attempted to
sequence the full IL28B coding region using highly qualified PCR
techniques with multiple primers to investigate whether there is
any novel polymorphism in the actual IL28B coding region that
might be related to the clearance of HBV infection. However,
because only native Korean subjects were recruited for this study,
our results should be interpreted with cautions and external
validation in other ethnic groups should be followed. Furthermore,
anti-HBs information was not available in our study, hence the
correlation between IL28B SNP and anti-HBs could not be
analyzed.
In conclusion, the SNP upstream of IL28B that has the strongest
genetic association with HCV recovery to date inversely influences
on HBV recovery. Thus, the effects of this SNP cannot be
generalized to chronic viral infections in which IFN-a treatment is
important. Additional studies are needed to understand the
mechanisms underlying the effects of this SNP in HBV infection.
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